Orion

Time 2022-08-04 20:42:33

Web Name: Orion

WebSite: http://www.orion.fi

ID:270726

Keywords:

Orion

Description:

en fi Menu Menu suomeksi

Orion Now

Other websites

FermionOrion Pharma Animal HealthWehale.lifeOrion countries

Orion Group

About OrionProducts and servicesPartnering and licensingInvestorsMediaCorporate GovernanceContact us

Careers at Orion

Open vacanciesWorking at OrionStudentsCareer stories

Research

Orion R&DResearch areasResearch for patient well-beingR&D pipelineScientific publications

Sustainability

PoliciesManagement of SustainabilitySustainability ReportsPatient organisation collaborationStories about responsibilityRaising the Bar

Health Professionals

Simdax.comDexdor.euWehale.life Orion Now  Orion Group Orion Group  Orion's century 1910s A superstar of Finnish chemistry It all began with Albin and woodfern Orion’s milestones in the 1910s 1920s A tireless promoter of children’s health One big family Orion’s milestones in the 1920s 1930s Finnishness as an advertising asset PR in the 1930s: Welcome to the Vallila plant! Orion’s milestones in the 1930s 1940s A miracle drug amidst the war Orion relocated Orion’s milestones in the 1940s 1950s A legendary school for laboratory assistants Finns’ favourite ointments Orion’s milestones in the 1950s 1960s The man behind the research An idyllic estate Orion’s milestones in the 1960s 1970s How can I help you? International horizons: rapid tests and Finnishness Orion’s milestones in the 1970s 1980s New address: Orionintie 1 “For manly pain” – from drugs to brands Orion’s milestones in the 1980s 1990s Joining forces with a competitor An inhaler that helps asthmatics and the atmosphere Orion’s milestones in the 1990s 2000s The long road to market The last hope for a heart patient Orion’s milestones in the 2000s 2010s Pink light to promote girls’ rights From a mobile phone factory to a pharmaceutical plant Orion’s milestone in the 2010s About Orion Management Board of Directors Executive management board Orion values Mission and strategy Partnering and licensing Partnering opportunities Alliance and Partner Management Excellence Products and Services Prescription drugs and self-care products Veterinary medicine Active Pharmaceutical Ingredients Contract manufacturing Investors Orion as an investment Market reviews Market reviews 2021 Market reviews 2020 Market reviews 2019 Market reviews 2018 Market reviews 2017 Market reviews 2016 Market reviews 2015 Market reviews 2014 Market reviews 2013 Market reviews 2012 Market reviews 2011 Market reviews 2010 Market reviews 2009 Market reviews 2008 Market reviews 2007 CEO's review CEO Timo Lappalainen's reviews 2021 CEO Timo Lappalainen's reviews 2020 CEO Timo Lappalainen's reviews 2019 CEO Timo Lappalainen's reviews 2018 CEO Timo Lappalainen's reviews 2017 CEO Timo Lappalainen's reviews 2016 CEO Timo Lappalainen's reviews 2015 CEO Timo Lappalainen's reviews 2014 CEO Timo Lappalainen’s reviews 2013 CEO Timo Lappalainen’s reviews 2012 CEO Timo Lappalainen's reviews 2011 CEO Timo Lappalainen's reviews 2010 CEO Timo Lappalainen’s reviews 2009 CEO Timo Lappalainen’s reviews 2008 CEO's reviews 2007 Financial Information Key figures Quarterly figures Credit programmes Outlook for 2022 Outlook for 2021 Outlook for 2020 Outlook for 2019 Outlook for 2018 Outlook for 2017 Outlook for 2016 Outlook for 2015 Outlook for 2014 Outlook for 2013 Outlook for 2012 Outlook for 2011 Outlook for 2010 Outlook for 2009 Outlook for 2008 Outlook for 2007 Outlook for 2006 Basis for outlook Accounting policies Calculation of key figures Financial reviews and presentations Capital Markets Days Financial Statements Other events Orion acquires Inovet's animal health business Share information Share capital and shares Share-related key figures Treasury shares Share price Alternative exchanges monitor Historical share prices Total return calculator Dividends Analysts Consensus estimates Shareholders Major shareholders by shares Major shareholders by votes Ownership structure Flagging notifications Insider register Conversion of shares Changes in shareholder's contacts Transactions of managers Messages to shareholders Annual General Meetings AGM 2022 AGM 2021 AGM 2020 AGM 2019 AGM 2018 AGM 2017 AGM 2016 AGM 2015 AGM 2014 AGM 2013 AGM 2012 AGM 2011 AGM 2010 AGM 2009 AGM 2008 AGM 2007 IR Calendar Silent period Archive Investor Relations CMD 2021 Media Stock Exchange Releases Press Releases Managers' transactions Subscribe to releases Material Bank Disclosure Policy Corporate Governance Corporate Governance Corporate Governance Statement AGM Board of Directors Activities and duties Principles Concerning Diversity of the Board of Directors Board members Mikael Silvennoinen Hilpi Rautelin Kari Jussi Aho Maziar Mike Doustdar Ari Lehtoranta Veli-Matti Mattila Eija Ronkainen Karen Lykke Sorensen Board Committees Nomination Committee Authorisations of the Board of Directors CEO and Executive Management Board Activities and duties Introductions of the Executive Management Board members Timo Lappalainen Satu Ahomäki Olli Huotari Liisa Hurme Jari Karlson Virve Laitinen Outi Vaarala Employee representative Jani Korhonen Remuneration Remuneration Report Remuneration Policy Share-based incentive plans Risks and internal control Strategic risks Operational risks Financial risks Compliance risks Insider administration Audit Articles of Association Modern Slavery and Human Trafficking Statement Contact us Drug safety and product information Locations and contact persons Sites and offices Pharmaceutical manufacturing Sales offices and representative offices Animal Health Fermion Contact persons Invoicing addresses Research Research  Orion R&D Orion's R&D Pipeline Research areas Research for patient well-being Living with a diagnosis Asthma ALS Prostate cancer Breast cancer Parkinson's disease Alzheimer's disease Drug development Scientific publications Clinical Research Privacy Statement Human Data Research Privacy Statement Orion Research Foundation Information about the Research Foundation The Administration of the Research Foundation Instructions for grant applicant Instructions for grant recipient Orion Research Foundation's grants Frequently asked questions Contacts Orion Research Foundation Grants for 2023: apply by 10 September 2022 Sustainability Sustainability  Management of sustainability Sustainability Agenda Patient safety and reliable supply of medications Environment Responsibility for Orionees Business ethics and transparency Policies Our approach to corporate responsibility Code of Conduct Human Resources Policy EHS Policy Quality Policy Anti-Corruption Policy Supplier requirements Pharmaceutical R&D Ethics Policy Bioethics and Animal Welfare Using Human Tissues, GMO and Stem Cells Ethics in the Clinical Research Phases Ethics in the Marketing Phase Sustainability Reports Sustainability Report 2021 Previous reports Patient organisation collaboration Healthcare professional collaboration Stories about responsibility Raising the Bar Careers at Orion Careers at Orion  Open Vacancies Applying for a job – questions and answers Working in the pharmaceutical industry Developing competence at Orion Building personnel well-being Career stories Health Professionals 

Orion takes robust action against falsified medicines – you too can support safe medication

A falsified medicinal product may hide a serious health risk. And even if nothing worse than ineffective, a falsified medicinal product still causes financial loss. You can avoid falsified products by buying your medicines in Finland. If you need to buy medicines abroad, make sure you purchase them from a licensed pharmacy.

Read more Orion Now 

Orion Research Foundation Grants for 2023: apply by 10 September 2022

Orion acquires Inovet’s animal health business

Through this acquisition, Orion’s Animal Health unit will expand its product portfolio and geographical presence and gain a production unit that is specialised in the manufacturing of veterinary medicines.

Read more

Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer

Read more Orion Now 

The training provided by Orion in cooperation with healthcare professionals improves patient safety – information about the training is disclosed annually

Orion ensures safe medical treatment by providing doctors and pharmacies with unbiased up-to-date information based on research. Transparency is essential in cooperation on training. Orion discloses the fees it has paid to professionals annually, in Finland usually in June.

Read more Sustainability 

Sustainability Report 2021

We enhance trust in Orion by operating responsibly in our daily work in everything we do. Our Sustainability Reports tell about the progress of our Sustainability Agenda.

Read more

What does the labelling on medicine packages tell us?

Working on safe and effective pharmaceutical products

Orion’s Pharmaceutical Sciences department serves as the bridge between research and commercial pharmaceutical product development. The department serves as a vital link in the chain of drug development, ensuring the safety of medicinal products in clinical trials and ensuring that a medicine is released and works as intended.

Read more Research 

Research areas

Orion develops new pharmaceuticals in three therapy areas. Orion’s pharmaceutical R&D focuses on the central nervous system, cancer and critical care, and inhalable Easyhaler® pulmonary drugs. Orion also develops veterinary and generic drugs. 

Read more

Scientific publications

A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.

Read more

Orion's R&D Pipeline

Read more Research 

Financial reviews and presentations

Orion published Half-Year Financial Report 1-6/2022 on Friday, 15 July 2022. The report, related presentation material and a link to a live webcast are available here.

Read more Orion Group 

AGM 2022

The Annual General Meeting of Orion Corporation was held on Wednesday 23 March 2022. The decisions and related material are available here.

Read more

Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer

Press Releases

6/28/2022 Orion publishes Half-Year Financial Report for January–June 2022 on Friday 15 July 2022 5/9/2022 The negotiations under the Act on Co-operation within Undertakings concerning Orion’s R&D have been completed – future focus on pain and oncology 5/6/2022 Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain 5/3/2022 U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for additional indication of darolutamide

Stock Exchange Releases

7/15/2022 Orion Group Half-Year Financial Report 1–6/2022 7/15/2022 Orion Corporation's financial reporting and Annual General Meeting in 2023 7/13/2022 Orion upgrades full-year outlook for 2022 following the USD 290 million upfront payment regarding ODM-208 agreement 7/13/2022 Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer

Working in the pharmaceutical industry

Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.

Read more Careers at Orion 

Students

Orion's Phase1 is a Summer trainee program that offers students for example in the fields of natural sciences, pharmacy, technology and economics possibilities to show their talent in an international pharmaceutical company. Please follow our page for more information about the Phase1 trainee program!

Read more Careers at Orion 

Orion is one of the most popular employers in Finland

Read more

Open Vacancies

See all open vacancies here.

Read more

Contract Manufacturing

Read more

Critical Care

One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.

Read more

For healthcare professionals

Are you a physician, vet, pharmacist or another healthcare professional? 'Health Professionals' site offers an easy access to our websites for professionals. 

Read more Change country   suomeksi

Orion Now

Follow us

FacebookTwitterTwitter (IR)Youtube

Orion Group

About OrionProducts and servicesPartnering and licensingInvestorsMediaSustainabilityCorporate GovernanceHealth professionals

Research

Orion R&DResearch areasResearch for patient well-beingR&D pipelineScientific publications

Careers at Orion

Open vacanciesWorking at OrionStudentsCareer stories

Other websites

FermionOrion Pharma Animal HealthOrion in other countries

Contact usPrivacyCookie PolicyAbout this websiteOrion Corporation, Orionintie 1A, 02200 Espoo, PO Box 65, FI-02101 Espoo, Finland. Phone +358 10 4261 © Copyright Orion Corporation.Company code, VAT 19992126.

TAGS:Orion

<<< Thank you for your visit >>>

Hot Websites